These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 16111461)
1. Use of goserelin in the treatment of breast cancer. Rody A; Loibl S; von Minckwitz G; Kaufmann M Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461 [TBL] [Abstract][Full Text] [Related]
2. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS; J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Sverrisdottir A; Nystedt M; Johansson H; Fornander T Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828 [TBL] [Abstract][Full Text] [Related]
5. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report]. Asaga S; Ando J; Arai T; Fujii H Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976 [TBL] [Abstract][Full Text] [Related]
6. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea. Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125 [TBL] [Abstract][Full Text] [Related]
7. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy? Malayeri R J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348 [No Abstract] [Full Text] [Related]
8. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Tan SH; Wolff AC Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122 [TBL] [Abstract][Full Text] [Related]
9. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women. Jonat W Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209 [TBL] [Abstract][Full Text] [Related]
10. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950 [TBL] [Abstract][Full Text] [Related]
11. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929 [TBL] [Abstract][Full Text] [Related]
12. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. de Haes H; Olschewski M; Kaufmann M; Schumacher M; Jonat W; Sauerbrei W; J Clin Oncol; 2003 Dec; 21(24):4510-6. PubMed ID: 14610048 [TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519 [TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related]
15. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589 [TBL] [Abstract][Full Text] [Related]
16. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations. Pritchard KI Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Baum M; Hackshaw A; Houghton J; Rutqvist ; Fornander T; Nordenskjold B; Nicolucci A; Sainsbury R; Eur J Cancer; 2006 May; 42(7):895-904. PubMed ID: 16545560 [TBL] [Abstract][Full Text] [Related]
18. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Michaud LB; Buzdar AU Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521 [TBL] [Abstract][Full Text] [Related]
19. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Fallowfield L; McGurk R; Dixon M Eur J Cancer; 2004 Nov; 40(16):2403-10. PubMed ID: 15519512 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]